With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For
May 21
U.S. Life Sciences Industry Analysis
UpdatedMay 23, 2024
DataAggregated Company Financials
Companies61
- 7D-1.3%
- 3M1.1%
- 1Y10.0%
- YTD5.0%
Over the last 7 days, the Life Sciences industry has dropped 1.3%, driven by Thermo Fisher Scientific declining 1.4%. This takes the industry's 12 month performance to a gain of 10%. As for the next few years, earnings are expected to grow by 17% per annum.
Industry Valuation and Performance
Has the U.S. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 23 May 2024 | US$736.1b | US$141.5b | US$12.4b | 38.4x | 59.2x | 5.2x |
| Sat, 20 Apr 2024 | US$682.0b | US$142.0b | US$12.8b | 41x | 53.3x | 4.8x |
| Mon, 18 Mar 2024 | US$741.1b | US$142.1b | US$12.8b | 43.9x | 57.7x | 5.2x |
| Wed, 14 Feb 2024 | US$697.5b | US$142.2b | US$12.8b | 40.3x | 54.3x | 4.9x |
| Fri, 12 Jan 2024 | US$692.4b | US$153.9b | US$14.2b | 35.5x | 48.9x | 4.5x |
| Sun, 10 Dec 2023 | US$644.8b | US$153.7b | US$14.0b | 35.2x | 46x | 4.2x |
| Tue, 07 Nov 2023 | US$595.2b | US$153.9b | US$11.0b | 30.3x | 54x | 3.9x |
| Thu, 05 Oct 2023 | US$640.4b | US$154.6b | US$11.2b | 32.8x | 57.2x | 4.1x |
| Sat, 02 Sep 2023 | US$735.8b | US$154.6b | US$11.2b | 33.1x | 65.7x | 4.8x |
| Mon, 31 Jul 2023 | US$739.7b | US$154.7b | US$11.6b | 31.5x | 63.6x | 4.8x |
| Wed, 28 Jun 2023 | US$677.2b | US$152.4b | US$12.5b | 29.3x | 54.2x | 4.4x |
| Fri, 26 May 2023 | US$671.4b | US$152.2b | US$12.5b | 27.8x | 53.7x | 4.4x |
| Sun, 23 Apr 2023 | US$728.5b | US$154.6b | US$10.8b | 29.9x | 67.4x | 4.7x |
| Tue, 21 Mar 2023 | US$700.7b | US$154.5b | US$10.8b | 26.2x | 64.8x | 4.5x |
| Thu, 16 Feb 2023 | US$749.3b | US$154.2b | US$8.6b | 32.1x | 87x | 4.9x |
| Sat, 14 Jan 2023 | US$761.4b | US$155.3b | US$8.5b | 30.6x | 89.3x | 4.9x |
| Mon, 12 Dec 2022 | US$761.9b | US$155.1b | US$8.8b | 28.4x | 86.8x | 4.9x |
| Wed, 09 Nov 2022 | US$707.8b | US$154.9b | US$9.1b | 26.4x | 78.1x | 4.6x |
| Fri, 07 Oct 2022 | US$749.3b | US$152.5b | US$17.0b | 24.9x | 44.1x | 4.9x |
| Sun, 04 Sep 2022 | US$753.3b | US$152.3b | US$17.3b | 28.7x | 43.5x | 4.9x |
| Tue, 02 Aug 2022 | US$829.5b | US$151.6b | US$18.2b | 33.7x | 45.5x | 5.5x |
| Thu, 30 Jun 2022 | US$718.3b | US$148.1b | US$20.1b | 30.5x | 35.7x | 4.9x |
| Sat, 28 May 2022 | US$773.5b | US$148.1b | US$20.1b | 31.8x | 38.5x | 5.2x |
| Mon, 25 Apr 2022 | US$806.5b | US$147.3b | US$25.4b | 33.7x | 31.8x | 5.5x |
| Wed, 23 Mar 2022 | US$873.3b | US$145.0b | US$25.3b | 36.9x | 34.5x | 6x |
| Fri, 18 Feb 2022 | US$832.6b | US$144.4b | US$25.3b | 37.6x | 32.9x | 5.8x |
| Sun, 16 Jan 2022 | US$878.1b | US$138.0b | US$27.3b | 39.9x | 32.1x | 6.4x |
| Tue, 14 Dec 2021 | US$963.9b | US$138.0b | US$27.3b | 43.1x | 35.3x | 7x |
| Thu, 11 Nov 2021 | US$952.9b | US$137.6b | US$27.1b | 45.8x | 35.1x | 6.9x |
| Sat, 09 Oct 2021 | US$709.0b | US$105.9b | US$18.6b | 46x | 38.2x | 6.7x |
| Mon, 06 Sep 2021 | US$755.0b | US$106.0b | US$18.6b | 51.1x | 40.6x | 7.1x |
| Wed, 04 Aug 2021 | US$714.4b | US$105.8b | US$18.7b | 47.1x | 38.3x | 6.8x |
Price to Earnings Ratio
34.4x
Current Industry PE
- Investors are optimistic on the American Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 59.2x which is higher than its 3-year average PE of 50.5x.
- The industry is trading close to its 3-year average PS ratio of 5.3x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 11% per year over the last three years.
- Meanwhile revenues for these companies have grown 13% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.19% | |
| Healthcare | -0.012% | |
| Life Sciences | -1.26% | |
| Clinical Research and Equipment | -1.26% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| DHR Danaher | US$267.19 | 1.4% +US$2.8b | 17.3% | PE48.6x | |
| RVTY Revvity | US$112.67 | 5.0% +US$661.4m | -3.8% | PE75.8x | |
| BRKR Bruker | US$78.29 | 1.0% +US$113.4m | 10.3% | PE28.3x | |
| ABCL AbCellera Biologics | US$3.86 | 4.3% +US$47.0m | -45.0% | PS31.7x | |
| SYNH Syneos Health | US$42.98 | 0.6% +US$24.9m | -8.8% | PE62.6x |
